Recent research presented at the 63rd ERA Congress reveals that dihydropyridine calcium-channel blockers (DCCBs), a common class of blood pressure medications, may be linked to worse kidney outcomes in patients with type 2 diabetes (T2D). The study analyzed data from 31,031 adults with T2D and found that those taking DCCBs in conjunction with standard kidney-protective therapies faced a 33% higher risk of major adverse kidney events compared to those on alternative antihypertensive treatments. These events included significant declines in kidney filtration capacity and progression to end-stage kidney disease. The research suggests that DCCBs may exacerbate kidney damage by preferentially relaxing blood vessels that supply blood to the kidney's filtering units, thereby increasing pressure within these structures. The lead author, Dr. Timna Agur, emphasized the need for further studies to determine the safest treatment strategies for patients with diabetic kidney disease (DKD), given the widespread prescription of DCCBs in this population.